-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ClQ2MER3b5Jntzj2SOn5iFEaDh6cug53ph4/fmoGRmtNeIptJk2OPdJDFowhiVg0 cyvnZTdv+Ww3RF44TNo1qg== 0000950124-05-006731.txt : 20051206 0000950124-05-006731.hdr.sgml : 20051206 20051206165945 ACCESSION NUMBER: 0000950124-05-006731 CONFORMED SUBMISSION TYPE: SC TO-I/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20051206 DATE AS OF CHANGE: 20051206 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0001041024 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 383317208 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-I/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-55735 FILM NUMBER: 051247600 BUSINESS ADDRESS: STREET 1: 30142 S WIXOM RD CITY: WIXOM STATE: MI ZIP: 48393 BUSINESS PHONE: 2489609009 MAIL ADDRESS: STREET 1: 30142 S WIXOM RD CITY: WIXOM STATE: MI ZIP: 48393 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0001041024 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 383317208 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-I/A BUSINESS ADDRESS: STREET 1: 30142 S WIXOM RD CITY: WIXOM STATE: MI ZIP: 48393 BUSINESS PHONE: 2489609009 MAIL ADDRESS: STREET 1: 30142 S WIXOM RD CITY: WIXOM STATE: MI ZIP: 48393 SC TO-I/A 1 k00448a2sctoviza.txt AMENDMENT NO.2 TO SCHEDULE TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ROCKWELL MEDICAL TECHNOLOGIES, INC. ---------------------------------------------------------------------------- (Name of Subject Company (issuer)) ROCKWELL MEDICAL TECHNOLOGIES, INC. ---------------------------------------------------------------------------- (Names of Filing Persons (identifying status as offeror, issuer or other person)) Common Share Purchase Warrants with an exercise price of $4.50 expiring on January 26, 2005 -------------------------------------------------------------------------- (Title of Class of Securities) 774 374 11 0 ---------------------------------------------------------------------------- (CUSIP Number of Class of Securities) ROBERT L. CHIOINI President and Chief Executive Officer Rockwell Medical Technologies, Inc. 30142 Wixom Road Wixom, Michigan 48393 Telephone: (248) 960-9009 ---------------------------------------------------------------------------- (Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons) Copy to: John P. Kanan, Esq. Honigman Miller Schwartz and Cohn LLP 2290 First National Building Detroit, Michigan 48226-3506 Telephone: (313) 465-7438 Telecopier: (313) 465-7439 Calculation of Filing Fee ----------------------------- ------------------------- Transaction valuation* Amount of filing fee $1,776,250 $209.06 ----------------------------- ------------------------- *Estimated solely for the purpose of computing the registration fee pursuant to Rule 0-11 of the Securities and Exchange Act of 1934, as amended, based on the value of the Common Share Purchase Warrants with an exercise price of $4.50 expiring January 26, 2006 computed in accordance with Rule 011-(a)(4), based on the average of the high and low sales prices of such Warrants on October 17, 2005, as quoted on The Nasdaq SmallCap Market. [X] Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. Amount Previously Paid: $1,493.32 Form or Registration No.: S-4 and SB-2 (file no. 333-127048) Filing Party: Rockwell Medical Technologies, Inc. Date Filed: July 29, 2005 [ ] Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates: [ ] third-party tender offer subject to Rule 14d-1. [X] issuer tender offer subject to Rule 13e-4. [ ] going-private transaction subject to Rule 13e-3. [ ] amendment to Schedule 13D under Rule 13d-2. Check the following box if the filling is a final amendment reporting the results of the tender offer: [X] This Amendment No. 2 to Issuer Tender Offer Statement on Schedule TO relates to the offer (the "Exchange Offer") by Rockwell Medical Technologies, Inc. (the "Company") to exchange Common Share Purchase Warrants with an exercise price of $3.90 expiring January 26, 2006 of the Company ("New Warrants") for validly tendered and accepted outstanding Common Share Purchase Warrants with an exercise price of $4.50 expiring January 26, 2006 of the Company ("Old Warrants") upon the terms and conditions contained in the prospectus dated October 17, 2005 (the "Prospectus") and the related Letter of Transmittal, which are parts of the Company's registration statement on Form S-4 and Form SB-2 (file no. 333-127048) initially filed with the Securities and Exchange Commission (the "Commission") on July 29, 2005, as amended by Amendment No. 1 to the Registration Statement filed with the Commission on September 22, 2005, Amendment No. 2 to the Registration Statement filed with the Commission on October 12, 2005 and Amendment No. 3 to the Registration Statement filed with the Commission on October 17, 2005 (as supplemented and/or amended, the "Registration Statement"), and the prospectus supplement dated November 14, 2005 and filed with the Commission on November 14, 2005, which are incorporated by reference herein. This Amendment No. 2 to Issuer Tender Offer Statement on Schedule TO is being filed to incorporate the press release dated December 6, 2005, which announced the final results of the Exchange Offer. 2 Item 12. Exhibits. (a)(1)(i) Prospectus dated October 17, 2005 (incorporated by reference to Part I of the Registration Statement). (a)(1)(ii) Letter of Transmittal (incorporated by reference to Exhibit 4.9 of the Registration Statement). (a)(1)(iii) Notice of Guaranteed Delivery (incorporated by reference to Exhibit 4.11 of the Registration Statement). (a)(1)(iv) Letter to Registered Holders (filed with original Issuer Tender Offer Statement on Schedule TO filed on October 20, 2005). (a)(1)(v) Letter to Depository Trust Company Participants (filed with original Issuer Tender Offer Statement on Schedule TO filed on October 20, 2005). (a)(1)(vi) Letter to Registered Holders and Depository Trust Company Participants (filed with Amendment No. 1 to the Issuer Tender Offer Statement on Schedule TO filed on November 15, 2005). (a)(2) None. (a)(3) None. (a)(4)(i) Prospectus dated October 17, 2005 (incorporated by reference to Part I of the Registration Statement). (a)(4)(ii) Prospectus Supplement dated November 14, 2005 (incorporated by reference to the Prospectus Supplement dated November 14, 2005 and filed on November 14, 2005). (a)(5) Press Release dated December 6, 2005. (b) None. (d) (d)(1) Form of Warrant Agreement the Company, American Stock Transfer & Trust Company, as Warrant Agent, and Mason Hill & Co., Inc. and J.W. Barclay & Co., Inc., as Underwriters, incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form SB-2, File No. 333-31991 initially filed on July 27, 1997. (d)(2) Form of Bridge Warrant issued by the Company, incorporated by reference to Exhibit 4.5 to the Company's Registration Statement on Form SB-2, File No. 333-31991 initially filed on July 27, 1997. (d)(3) Registration Rights Agreement among the Company and the holders of certain of the Company's Common Share Purchase Warrants, incorporated by reference to Exhibit 4.6 to the Company's Registration Statement on Form SB-2, File No. 333-31991 initially filed on July 27, 1997. (d)(4) Rockwell Medical Technologies, Inc. 1997 Stock Option Plan (and option agreements issued pursuant to the Plan), incorporated by reference to the Proxy Statement for the Annual Meeting of Shareholders filed on April 21, 2005. (d)(5) Form of Warrant Agreement between the Company and American Stock Transfer & Trust Company, as Warrant Agent, incorporated by reference to Exhibit 4.7 to the Company Registration Statement on Forms SB-2 and S-4 initially filed on July 29, 2005. (d)(6) Form of Warrant Exchange Agreement between the Company and American Stock Transfer & Trust Company, as Exchange Agent , incorporated by reference to Exhibit 4.10 to the Company Registration Statement on Forms SB-2 and S-4 initially filed on July 29, 2005. (d)(7) Common Share Purchase Warrant issued by the Company to Thomas Anderl (filed with original Issuer Tender Offer Statement on Schedule TO filed on October 20, 2005). (g) None. (h) Opinion of Honigman Miller Schwartz and Cohn LLP (incorporated by reference to Exhibit 8.1 to the Registration Statement). 3 Signature After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. /s/ Thomas E. Klema ------------------------------------------------------ (Signature) Thomas E. Klema, Chief Financial Officer ------------------------------------------------------ (Name and Title) December 6, 2005 ------------------------------------------------------ (Date) 4 EX-99.(A)(5) 2 k00448a2exv99wxayx5y.txt PRESS RELEASE, DATED DECEMBER 6, 2005 [ROCKWELL MEDICAL TECHNOLOGIES, INC. LOGO] COMPANY PRESS RELEASE Contact: Thomas Klema (248) 960-9009 ROCKWELL MEDICAL TECHNOLOGIES, INC. COMPLETES WARRANT EXCHANGE OFFER WIXOM, MICHIGAN, December 6, 2005 - Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a leading, innovative dialysis products manufacturer serving the healthcare industry, announced today that it completed its warrant exchange offer. Warrant holders exchanged 3,270,303 warrants, or approximately 90% of the old warrants. The new warrant (Cusip no. 774374-12-8) is traded on the Nasdaq Exchange under the symbol RMTIZ (Nasdaq:RMTIZ). Both the old warrant (Nasdaq: RMTIW) and the new warrant (Nasdaq:RMTIZ) will expire on January 26, 2006. The new warrants have an exercise price of $3.90 per Common Share. Rockwell expects it could raise gross proceeds of approximately $12,750,000 if all of the new warrants are exercised by their expiration on January 26, 2006. Rockwell intends to use the majority of any net proceeds to obtain FDA approval for its proprietary iron-delivery product. If Rockwell obtains FDA approval, Rockwell expects its proprietary iron-delivery product to compete for the estimated $300,000,000 U.S. market for iron therapy for dialysis patients. Rockwell also anticipates using a portion of any proceeds for the expansion of its business including additional working capital and may include expansion of its production and distribution network. Rockwell reported sales growth of 61% and earnings per share of $.04 in the first three quarters of 2005. Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has experienced an average annual increase of approximately 6%-8% over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate(R) Dry Acid Concentrate Mixing System, RenalPure(R) Liquid Acid Concentrate, SteriLyte(R) Liquid Bicarbonate Concentrate, RenalPure(R) Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items. Rockwell is currently in the process of developing and gaining FDA approval of a proprietary iron-delivery product which will be administered to dialysis patients via dialysate. Visit Rockwell's website at www.rockwellmed.com for more information. Certain statements in this press release constitute "forward-looking statements". These statements include statements regarding the amount of expected proceeds from the exercise of warrants, the use of those proceeds, and Rockwell's expectations with respect to its' iron-delivery product. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, the market price of Rockwell's common shares not exceeding the exercise price of the new warrants, the failure of warrant holders to exercise their warrants, the failure of Rockwell to obtain FDA approval of its iron-delivery product, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports and registrations statements filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties. -----END PRIVACY-ENHANCED MESSAGE-----